Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2019 01:00 ET | Source: Novartis Pharma AG

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million,...
July 18, 2019 01:00 ET | Source: Novartis Pharma AG

Novartis au 2e trimestre: fortes ventes, croissance à deux chiffres du résultat opérationnel core et lancements de Zolgensma et de Piqray; prévision des ventes et du résultat revue à la hausse

Chiffre d'affaires net des activités poursuivies[1] en hausse de 8% (tcc[2], +4% USD) soutenu par: Cosentyx: USD 858 millions, +25% (tcc) stimulé principalement par le maintien de la forte...
July 18, 2019 01:00 ET | Source: Novartis Pharma AG

Novartis erzielt im zweiten Quartal starke Umsätze, eine zweistellige Steigerung des operativen Kernergebnisses und lanciert Zolgensma und Piqray; Anhebung der Umsatz- und Gewinnerwartung

Der Nettoumsatz der fortzuführenden Geschäftsbereiche[1] steigt aufgrund folgender Beiträge um 8% (kWk[2], +4% USD): Cosentyx erzielt einen Umsatz von USD 858 Millionen (+25% kWk), vor allem dank...
July 16, 2019 01:15 ET | Source: Novartis Pharma AG

FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from...
July 11, 2019 16:30 ET | Source: Novartis Pharma AG

Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention

After review of clinical data from the Generation Program studies, the sponsors concluded that the potential benefit for participants taking CNP520 no longer outweighs the risk Basel, July 11,...
July 02, 2019 01:30 ET | Source: Novartis Pharma AG

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

Sandoz gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer[1] with activating mutations of EGFR-TK[1] More than 300,000 European men and women...
July 02, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)

Data presented again at European Academy of Neurology (EAN) congress show that baseline neurofilament light chain (NfL) levels can predict cognitive impairment and disability worsening in...
July 01, 2019 11:30 ET | Source: Novartis Pharma AG

Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio

Basel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both...
July 01, 2019 01:30 ET | Source: Novartis Pharma AG

Novartis data show Aimovig® cuts acute migraine medication days by half in patients who failed prior preventive therapies

Data from the active treatment phase of STRIVE investigated efficacy and safety of Aimovig (erenumab) 70 and 140 mg in episodic migraine patients with prior preventive treatment failures ...
July 01, 2019 01:15 ET | Source: Novartis Pharma AG

Novartis data underpin long-term efficacy of Aimovig® where other treatments have failed

Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive...